← Supernus Pharmaceuticals overview

Supernus Pharmaceuticals vs Sichuan Kelun Pharmaceutical: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Supernus Pharmaceuticals Inc (SUPN)

Q3 2026
▲2

Supernus- Indivior merger reshapes CNS pharma, Q2 revenue beats

  • All-stock merger with Indivior Supernus agreed to merge with Indivior in an all-stock deal, creating a CNS-focused company with $2.2B pro forma revenue and $125M cost synergies. Supernus shareholders get 1.5401 Indivior shares per share. The combined firm keeps the SUPN ticker and CEO. This is the main driver, boosting scale and pipeline.

    The merger is the biggest new event, directly reshaping Supernus and driving the stock's recent surge.

  • Q2 revenue beat and strong growth Supernus reported Q2 revenue of $211.3 million, up 27.7% year over year and 2.8% above estimates. This shows the core business is growing faster than expected, supporting the stock price.

    The Q2 revenue beat is new and confirms operational strength, a key fundamental driver.

July 2026
▲2

Supernus- Indivior merger reshapes CNS pharma, Q2 revenue beats

  • All-stock merger with Indivior Supernus agreed to merge with Indivior in an all-stock deal, creating a CNS-focused company with $2.2B pro forma revenue and $125M cost synergies. Supernus shareholders get 1.5401 Indivior shares per share. The combined firm keeps the SUPN ticker and CEO. This is the main driver, boosting scale and pipeline.

    The merger is the biggest new event, directly reshaping Supernus and driving the stock's recent surge.

  • Q2 revenue beat and strong growth Supernus reported Q2 revenue of $211.3 million, up 27.7% year over year and 2.8% above estimates. This shows the core business is growing faster than expected, supporting the stock price.

    The Q2 revenue beat is new and confirms operational strength, a key fundamental driver.

Latest
▲2

Supernus- Indivior merger reshapes CNS pharma, Q2 revenue beats

  • All-stock merger with Indivior Supernus agreed to merge with Indivior in an all-stock deal, creating a CNS-focused company with $2.2B pro forma revenue and $125M cost synergies. Supernus shareholders get 1.5401 Indivior shares per share. The combined firm keeps the SUPN ticker and CEO. This is the main driver, boosting scale and pipeline.

    The merger is the biggest new event, directly reshaping Supernus and driving the stock's recent surge.

  • Q2 revenue beat and strong growth Supernus reported Q2 revenue of $211.3 million, up 27.7% year over year and 2.8% above estimates. This shows the core business is growing faster than expected, supporting the stock price.

    The Q2 revenue beat is new and confirms operational strength, a key fundamental driver.

Sichuan Kelun Pharmaceutical Co Ltd (002422.CS)

Q3 2026
▲3▼1

Kelun's profit rises on drug wins and buybacks, but bribery claim and pledges weigh

  • New ADC drug enters clinical trials A Kelun subsidiary won Chinese approval to start human testing of SKB565, a new dual-payload ADC for advanced solid tumors. It is the first of its kind from Kelun Biotech, and success could add a valuable future growth engine, though it is years from sales.

    Shows pipeline progress that can lift long-term growth expectations for the stock.

  • National procurement wins boost sales outlook Kelun and its units won tentative selection for more than ten products in China's 12th national bulk-buy drug round, including heart and cancer medicines. Winning means guaranteed hospital sales volumes, supporting revenue even if prices are lower.

    Directly increases expected product demand and market share, a core earnings driver.

  • Profit grows and dividend plus buyback support stock First-half net profit rose 12.7% to 1.128 billion yuan, with second-quarter profit up 48% from the prior quarter, despite slightly lower revenue. The company also plans a cash dividend and has been buying back shares, signaling confidence and returning cash to holders.

    Earnings growth and shareholder returns are the main fundamental supports for the share price.

  • Bribery claim and owner pledges create risk A whistleblower letter alleged commercial bribery tied to a key Kelun drug; the subsidiary denies it and threatens legal action. Separately, controlling shareholder Liu Gexin added to pledged shares for personal funding. Both raise uncertainty and could pressure the stock if they worsen.

    These are the main counterweights that could hurt sentiment and valuation.

September 2026
▲3▼1

Kelun's profit rises on drug wins and buybacks, but bribery claim and pledges weigh

  • New ADC drug enters clinical trials A Kelun subsidiary won Chinese approval to start human testing of SKB565, a new dual-payload ADC for advanced solid tumors. It is the first of its kind from Kelun Biotech, and success could add a valuable future growth engine, though it is years from sales.

    Shows pipeline progress that can lift long-term growth expectations for the stock.

  • National procurement wins boost sales outlook Kelun and its units won tentative selection for more than ten products in China's 12th national bulk-buy drug round, including heart and cancer medicines. Winning means guaranteed hospital sales volumes, supporting revenue even if prices are lower.

    Directly increases expected product demand and market share, a core earnings driver.

  • Profit grows and dividend plus buyback support stock First-half net profit rose 12.7% to 1.128 billion yuan, with second-quarter profit up 48% from the prior quarter, despite slightly lower revenue. The company also plans a cash dividend and has been buying back shares, signaling confidence and returning cash to holders.

    Earnings growth and shareholder returns are the main fundamental supports for the share price.

  • Bribery claim and owner pledges create risk A whistleblower letter alleged commercial bribery tied to a key Kelun drug; the subsidiary denies it and threatens legal action. Separately, controlling shareholder Liu Gexin added to pledged shares for personal funding. Both raise uncertainty and could pressure the stock if they worsen.

    These are the main counterweights that could hurt sentiment and valuation.

Latest
▲3▼1

Kelun's profit rises on drug wins and buybacks, but bribery claim and pledges weigh

  • New ADC drug enters clinical trials A Kelun subsidiary won Chinese approval to start human testing of SKB565, a new dual-payload ADC for advanced solid tumors. It is the first of its kind from Kelun Biotech, and success could add a valuable future growth engine, though it is years from sales.

    Shows pipeline progress that can lift long-term growth expectations for the stock.

  • National procurement wins boost sales outlook Kelun and its units won tentative selection for more than ten products in China's 12th national bulk-buy drug round, including heart and cancer medicines. Winning means guaranteed hospital sales volumes, supporting revenue even if prices are lower.

    Directly increases expected product demand and market share, a core earnings driver.

  • Profit grows and dividend plus buyback support stock First-half net profit rose 12.7% to 1.128 billion yuan, with second-quarter profit up 48% from the prior quarter, despite slightly lower revenue. The company also plans a cash dividend and has been buying back shares, signaling confidence and returning cash to holders.

    Earnings growth and shareholder returns are the main fundamental supports for the share price.

  • Bribery claim and owner pledges create risk A whistleblower letter alleged commercial bribery tied to a key Kelun drug; the subsidiary denies it and threatens legal action. Separately, controlling shareholder Liu Gexin added to pledged shares for personal funding. Both raise uncertainty and could pressure the stock if they worsen.

    These are the main counterweights that could hurt sentiment and valuation.